JP2023526853A - ウイルス性呼吸器感染症の処置 - Google Patents

ウイルス性呼吸器感染症の処置 Download PDF

Info

Publication number
JP2023526853A
JP2023526853A JP2022571157A JP2022571157A JP2023526853A JP 2023526853 A JP2023526853 A JP 2023526853A JP 2022571157 A JP2022571157 A JP 2022571157A JP 2022571157 A JP2022571157 A JP 2022571157A JP 2023526853 A JP2023526853 A JP 2023526853A
Authority
JP
Japan
Prior art keywords
antagonist
subject
cells
antibody
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526853A5 (https=
Inventor
ムハンマド タヒア ナッサー，サイード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosirius Ltd
Original Assignee
Biosirius Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosirius Ltd filed Critical Biosirius Ltd
Publication of JP2023526853A publication Critical patent/JP2023526853A/ja
Publication of JP2023526853A5 publication Critical patent/JP2023526853A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022571157A 2020-05-19 2021-05-19 ウイルス性呼吸器感染症の処置 Pending JP2023526853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2007404.3 2020-05-19
GBGB2007404.3A GB202007404D0 (en) 2020-05-19 2020-05-19 Treatment for viral respiratory infections
PCT/GB2021/051207 WO2021234381A1 (en) 2020-05-19 2021-05-19 Treatment for viral respiratory infections

Publications (2)

Publication Number Publication Date
JP2023526853A true JP2023526853A (ja) 2023-06-23
JP2023526853A5 JP2023526853A5 (https=) 2024-02-13

Family

ID=71135334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571157A Pending JP2023526853A (ja) 2020-05-19 2021-05-19 ウイルス性呼吸器感染症の処置

Country Status (12)

Country Link
US (1) US20230192838A1 (https=)
EP (1) EP4153302B1 (https=)
JP (1) JP2023526853A (https=)
KR (1) KR20230053549A (https=)
CN (1) CN116406289A (https=)
AU (1) AU2021276614A1 (https=)
CA (1) CA3179461A1 (https=)
ES (1) ES2982939T3 (https=)
GB (1) GB202007404D0 (https=)
HU (1) HUE067327T2 (https=)
PL (1) PL4153302T3 (https=)
WO (1) WO2021234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508511A (ja) * 2010-12-20 2014-04-10 メドイミューン・リミテッド 抗ｉｌ−１８抗体およびそれらの使用
JP2016536332A (ja) * 2013-09-05 2016-11-24 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US20230173021A1 (en) * 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508511A (ja) * 2010-12-20 2014-04-10 メドイミューン・リミテッド 抗ｉｌ−１８抗体およびそれらの使用
JP2016536332A (ja) * 2013-09-05 2016-11-24 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUTOIMMUN. REV., vol. vol.19, issue 6, JPN6025009952, April 2020 (2020-04-01), pages 1 - 7, ISSN: 0005759922 *
IMMUNOLOGY, vol. vol.114, issue 1, JPN6025009951, 2005, pages 112 - 120, ISSN: 0005759921 *
LANCET, vol. vol.395, issue 10229, JPN6025009953, March 2020 (2020-03-01), pages 1054 - 1062, ISSN: 0005759923 *
POL. ARCH. INTERN. MED., vol. vol.130, issue 5, JPN6025009825, April 2020 (2020-04-01), pages 390 - 399, ISSN: 0005759924 *
順天堂医学, vol. 50, no. 2, JPN6025009954, 2004, pages 161 - 165, ISSN: 0005759925 *

Also Published As

Publication number Publication date
CN116406289A (zh) 2023-07-07
HUE067327T2 (hu) 2024-10-28
AU2021276614A1 (en) 2023-01-05
GB202007404D0 (en) 2020-07-01
WO2021234381A1 (en) 2021-11-25
PL4153302T3 (pl) 2024-10-07
US20230192838A1 (en) 2023-06-22
EP4153302A1 (en) 2023-03-29
EP4153302B1 (en) 2024-05-29
EP4153302C0 (en) 2024-05-29
CA3179461A1 (en) 2021-11-25
ES2982939T3 (es) 2024-10-21
KR20230053549A (ko) 2023-04-21

Similar Documents

Publication Publication Date Title
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
Sokolowska et al. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI)
WO2021202563A1 (en) Methods of treating coronavirus infection
EP3703818B1 (en) Il-4r antagonist for use in a method for treating or preventing asthma
TWI857389B (zh) 治療發炎症狀的方法
JP2016536332A (ja) 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
WO2021211940A1 (en) Methods for treating a complement mediated disorder caused by viruses
CN112424226B (zh) 用于治疗重度哮喘的抗cd6抗体
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
EP4153302B1 (en) Treatment for viral respiratory infections
WO2023067348A1 (en) Treatment for virally-induced pneumonia
JP2023518814A (ja) Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
US20230365712A1 (en) Notch4 antibodies and uses thereof
US20160355601A1 (en) Methods and Compositions for the Treatment of Pancreatic Cancer
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
EP4107186A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
KR20240008231A (ko) 급성호흡곤란증후군의 치료 또는 예방 방법
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
RU2796586C2 (ru) Антитела к cd6 для лечения тяжелой астмы
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
KR20130110225A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
KR20080093016A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423